IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) and Delcath Systems (NASDAQ:DCTH – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.
Profitability
This table compares IDEXX Laboratories and Delcath Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IDEXX Laboratories | 25.36% | 71.04% | 33.99% |
| Delcath Systems | 6.05% | 5.56% | 4.98% |
Earnings and Valuation
This table compares IDEXX Laboratories and Delcath Systems”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IDEXX Laboratories | $4.66 billion | 11.89 | $1.06 billion | $14.83 | 47.45 |
| Delcath Systems | $109.96 million | 6.21 | $2.70 million | $0.16 | 122.72 |
IDEXX Laboratories has higher revenue and earnings than Delcath Systems. IDEXX Laboratories is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings for IDEXX Laboratories and Delcath Systems, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IDEXX Laboratories | 0 | 6 | 7 | 0 | 2.54 |
| Delcath Systems | 0 | 1 | 2 | 1 | 3.00 |
IDEXX Laboratories currently has a consensus price target of $717.27, indicating a potential upside of 1.93%. Delcath Systems has a consensus price target of $29.33, indicating a potential upside of 49.39%. Given Delcath Systems’ stronger consensus rating and higher probable upside, analysts plainly believe Delcath Systems is more favorable than IDEXX Laboratories.
Risk and Volatility
IDEXX Laboratories has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.
Institutional and Insider Ownership
87.8% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 0.8% of IDEXX Laboratories shares are held by company insiders. Comparatively, 19.4% of Delcath Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
IDEXX Laboratories beats Delcath Systems on 10 of the 15 factors compared between the two stocks.
About IDEXX Laboratories
IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.
About Delcath Systems
Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
